John Andrews has more than 35 years of experience in the development of new therapeutics and vaccines for viral diseases as well as experience in other therapeutic areas such as oncology, autism, cardiovascular, and pulmonary. He takes a highly strategic approach to regulatory affairs and drug development, often acts as head of regulatory and a regulatory advisor, as well as an author of regulatory submissions.
Prior to joining Halloran, John spent 10 years as a consultant to several different biotech companies and continued his work in viral diseases including SARS-CoV-2. John began his career in the pharmaceutical industry during the 1980-1990 HIV epidemic and had the good fortune of being involved in the development of the first antivirals (acyclovir for HSV and zidovudine for HIV). John was a founder of PharmaResearch, a CRO specializing in HIV and rare diseases.
John earned a Doctor of Philosophy in virology/immunology/microbiology from the University of North Carolina/Chapel Hill and a Masters Degree in Biochemistry from Purdue University.